No Data
Three clinical studies of Ascentage Pharma's Bcl-2 inhibitor APG-2575 were selected for presentation at the 2024 ASH conference, including one oral presentation!
Rockville City, Maryland, usa and Suzhou, china, November 6, 2024 / PRNewswire / - Ascentage Pharma (6855.HK), a leading biomedical company dedicated to developing innovative drugs in fields such as oncology, announced today that its key product APG-2575 (Lisaftoclax) has a total of 3 clinical advancements selected for the 66th American Society of Hematology (ASH) annual meeting, including one oral presentation. This marks the third consecutive year that this product's clinical advancements have been selected for the ASH annual meeting.
【2024 ASH】Seven consecutive championships! Novartis with multiple studies selected for the seventh time, one of which received an oral presentation.
Rockville City, Maryland, USA, and Suzhou, China, November 6, 2024 / PR Newswire / - ASLAN Pharmaceuticals (6855.HK), a leading biomedical company dedicated to developing innovative drugs in oncology and other fields, announced today that its original Type 1 innovative drug, orelabutinib (trade name: Nalik), has multiple clinical developments selected for the 66th American Society of Hematology (ASH) Annual Meeting, including one oral presentation. This marks the seventh consecutive year of clinical progress for this drug variety being selected for an oral presentation at the ASH Annual Meeting.
ASCO-B (06855): Multiple clinical advancements of Darolutamide, Lisaftoclax, APG-5918, and APG-2449 will be presented at the 2024 American Society of Hematology Annual Meeting (ASH), with two of them receiving oral presentations.
Aier Sheng Pharmaceutical - B (06855) issued an announcement that the company has a total of 4 new drugs under research (Nailike, Lisafto...
CICC: Upgraded Aier Ophthalmology-B (06855) target price to HK$55, maintaining 'outperform industry' rating.
Recently, the company announced that the company's original class 1 new drug, FAK/ALK/ROS1 triple tyrosine kinase inhibitor (TKI) APG-2449, has been approved by the National Medical Products Administration, and will conduct two Phase III clinical studies for second-generation ALK TKI resistant or intolerant non-small cell lung cancer (NSCLC) or first-line ALK-positive advanced NSCLC.
This week's Hong Kong stock bull stocks | Technology boom suddenly swept the market! Semiconductor Manufacturing International Corporation surged nearly 20% during the week; a series of bullish policies have been introduced this year, with Zai Lab leading
This week, the Hang Seng Index fell by 2.11% to 20,804.11 points; during the same period, the Hang Seng Tech Index fell by 2.86% to 4,600.85 points; the Hang Seng China Enterprises Index fell by 1.95% to 7,471.95 points during the same period.
Express News | National Medical Products Administration: Deploys pilot work on segmented production reform of biological products.
No Data
No Data